Moreover, the study also documented a high expression of APOJ in patients with <T2 stage breast cancer, thus suggesting the immunostaining of APOJ as a predictive tool in addition to its role as a prognostic factor for recurrence [62]. This evidence concerns the gene CLU and breast carcinoma.